Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCN-CP01 anti-CD19 CAR T study in relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma
NL-OMON60863Phase 2Completed
- Sponsor
- Galapagos NV
- Start
- Feb 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of GLPG5301 in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Galapagos NV. Primary endpoints: Incidence of adverse events and dose-limiting toxicities and Best objective response rate. Started Feb 2022; status: completed.
02
Drugs
GLPG5301
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on NL-OMON60863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60863.